References
Key articles
Department of Health. Minimise transmission risk of CJD and vCJD in healthcare settings. Nov 2021 [internet publication].Full text
Centers for Disease Control and Prevention. BSE (Bovine spongiform encephalopathy, or mad cow disease). Sep 2021 [internet publication].Full text
American College of Radiology. ACR appropriateness criteria: movement disorders and neurodegenerative diseases. 2019 [internet publication].Full text
Reference articles
1. Mastrianni JA, Roos RP. The prion diseases. Semin Neurol. 2000;20(3):337-52. Abstract
2. Will RG, Alperovitch A, Poser S, et al. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. EU Collaborative Study Group for CJD. Ann Neurol. 1998 Jun;43(6):763-7. Abstract
3. Prusiner SB. Shattuck lecture: neurodegenerative diseases and prions. N Engl J Med. 2001 May 17;344(20):1516-26.Full text Abstract
4. Prusiner SB. The prion diseases. Brain Pathol. 1998 Jul;8(3):499-513. Abstract
6. Kong Q, Surewicz WK, Petersen RB, et al. Inherited prion diseases. In: Prusiner SB, ed. Prion biology and disease. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2004:673-776.
7. Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016 Jan 20;8(322):322ra9.Full text Abstract
8. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull. 2003;66:255-265.Full text Abstract
9. Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology. 2000 Oct 24;55(8):1075-81. Abstract
10. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia. 2010 Mar;16(2):296-304. Abstract
11. Will RG, Zeidler M, Stewart GE, et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol. 2000 May;47(5):575-82. Abstract
12. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996 Apr 6;347(9006):921-5. Abstract
13. Heath CA, Cooper SA, Murray K, et al. Diagnosing variant Creutzfeldt-Jakob disease: a retrospective analysis of the first 150 cases in the UK. J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):646-51. Abstract
14. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain. 2006 Sep;129(Pt 9):2278-87.Full text Abstract
15. Panagariya A, Jain RS, Sharma AK. Stroke like presentation of Creutzfeldt Jakob disease: an unusual variant. J Assoc Physicians India. 1999 May;47(5):548-50. Abstract
16. Jacobs DA, Lesser RL, Mourelatos Z, et al. The Heidenhain variant of Creutzfeldt-Jakob disease: clinical, pathologic, and neuroimaging findings. J Neuroophthalmol. 2001 Jun;21(2):99-102. Abstract
17. Kropp S, Schulz-Schaeffer WJ, Finkenstaedt M, et al. The Heidenhain variant of Creutzfeldt-Jakob disease. Arch Neurol. 1999 Jan;56(1):55-61.Full text Abstract
18. Poon MA, Stuckey S, Storey E. MRI evidence of cerebellar and hippocampal involvement in Creutzfeldt- Jakob disease. Neuroradiology. 2001 Sep;43(9):746-9. Abstract
19. Belay ED, Holman RC, Schonberger LB. Creutzfeldt-Jakob disease surveillance and diagnosis. Clin Infect Dis. 2005 Sep 15;41(6):834-6. Abstract
20. Laske C, Gefeller O, Pfahlberg A, et al. The effect of stress on the onset and progression of Creutzfeldt-Jakob disease: results of a German pilot case-control study. Eur J Epidemiol. 1999 Aug;15(7):631-5. Abstract
21. Will R. Variant Creutzfeldt-Jakob disease. Folia Neuropathol. 2004;42(suppl A):77-83. Abstract
22. Kovács GG, Puopolo M, Ladogana A, et al. Genetic prion disease: the EUROCJD experience. Hum Genet. 2005 Nov;118(2):166-74. Abstract
23. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999 Aug;46(2):224-33. Abstract
24. Hamaguchi T, Noguchi-Shinohara M, Nozaki I, et al. The risk of iatrogenic Creutzfeldt-Jakob disease through medical and surgical procedures. Neuropathology. 2009 Oct;29(5):625-31. Abstract
25. Peretz D, Supattapone S, Giles K, et al. Inactivation of prions by acidic sodium dodecyl sulfate. J Virol. 2006 Jan;80(1):322-31.Full text Abstract
26. Douet JY, Lacroux C, Aron N, et al. Distribution and quantitative estimates of variant Creutzfeldt-Jakob Disease prions in tissues of clinical and asymptomatic patients. Emerg Infect Dis. 2017 Jun;23(6):946-956.Full text Abstract
27. Department of Health. Minimise transmission risk of CJD and vCJD in healthcare settings. Nov 2021 [internet publication].Full text
28. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 1997 Oct 2;389(6650):498-501. Abstract
29. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004 Aug 7-13;364(9433):527-9. Abstract
30. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004 Feb 7;363(9407):417-21. Abstract
31. Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet. 2006 Dec 9;368(9552):2061-7. Abstract
32. Dorsey K, Zou S, Schonberger LB, et al. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Transfusion. 2009 May;49(5):977-84. Abstract
33. Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev. 2008 Jan;22(1):58-69. Abstract
34. Goold R, Rabbanian S, Sutton L, et al. Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun. 2011;2:281.Full text Abstract
35. Norrby E. Prions and protein-folding diseases. J Intern Med. 2011 Jul;270(1):1-14. Abstract
36. Kretzschmar HA, Ironside JW, DeArmond SJ, et al. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol. 1996 Sep;53(9):913-20. Abstract
37. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet. 1999 Jan 16;353(9148):183-9. Abstract
38. DeArmond SJ, Prusiner SB. Perspectives on prion biology, prion disease pathogenesis, and pharmacologic approaches to treatment. Clin Lab Med. 2003 Mar;23(1):1-41. Abstract
39. Freixes M, Rodriguez A, Dalfo E, et al. Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol Aging. 2006 Dec;27(12):1807-15. Abstract
40. Bleich S, Kropp S, Degner D, et al. Creutzfeldt-Jakob disease and oxidative stress. Acta Neurol Scand. 2000 May;101(5):332-4. Abstract
41. Minghetti L, Pocchiari M. Cyclooxygenase-2, prostaglandin E2, and microglial activation in prion diseases. Int Rev Neurobiol. 2007;82:265-75. Abstract
42. Bouzamondo-Bernstein E, Hopkins SD, Spilman P, et al. The neurodegeneration sequence in prion diseases: evidence from functional, morphological and ultrastructural studies of the GABAergic system. J Neuropathol Exp Neurol. 2004 Aug;63(8):882-99. Abstract
43. DeArmond SJ, Sanchez H, Yehiely F, et al. Selective neuronal targeting in prion disease. Neuron. 1997 Dec;19(6):1337-48. Abstract
44. Prusiner SB, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10608-12.Full text Abstract
45. Bueler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993 Jul 2;73(7):1339-47. Abstract
46. Sailer A, Bueler H, Fischer M, et al. No propagation of prions in mice devoid of PrP. Cell. 1994 Jul 1;77(7):967-8. Abstract
47. Legname G, Baskakov IV, Nguyen HO, et al. Synthetic mammalian prions. Science. 2004 Jul 30;305(5684):673-6. Abstract
48. Makarava N, Kovacs GG, Bocharova O, et al. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol. 2010 Feb;119(2):177-87. Abstract
49. Prusiner SB. Detecting mad cow disease. Sci Am. 2004 Jul;291(1):86-93. Abstract
50. Brandel JP, Vlaicu MB, Culeux A, et al. Variant Creutzfeldt-Jakob Disease Diagnosed 7.5 Years after Occupational Exposure. N Engl J Med. 2020 Jul 2;383(1):83-85.Full text Abstract
51. UK Health Protection Agency. Variant CJD and plasma products. January 2007. [internet publication].Full text
52. Puopolo M, Ladogana A, Vetrugno V, et al. Transmission of sporadic Creutzfeldt-Jakob disease by blood transfusion: risk factor or possible biases. Transfusion. 2011 Jul;51(7):1556-66. Abstract
53. Creutzfeldt-Jakob Disease International Surveillance Network. CJD surveillance data 1993-2013. [internet publication].Full text
54. Centers for Disease Control and Prevention. BSE (Bovine spongiform encephalopathy, or mad cow disease). Sep 2021 [internet publication].Full text
55. World Organisation for Animal Health. Number of reported cases of bovine spongiform encephalopathy (BSE) in farmed cattle worldwide* (excluding the United Kingdom). 2017. [internet publication].Full text
56. Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci US. 1999 Dec 21;96(26):15137-42.Full text Abstract
57. Williams ES. Chronic wasting disease. Vet Pathol. 2005 Sep;42(5):530-49. Abstract
58. Waddell L, Greig J, Mascarenhas M, et al. Current evidence on the transmissibility of chronic wasting disease prions to humans: a systematic review. Transbound Emerg Dis. 2017 [Epub ahead of print].Full text Abstract
59. Miller MW, Williams ES. Chronic wasting disease of cervids. Curr Top Microbiol Immunol. 2004;284:193-214. Abstract
60. Angers RC, Browning SR, Seward TS, et al. Prions in skeletal muscles of deer with chronic wasting disease. Science. 2006 Feb 24;311(5764):1117. Abstract
61. Mawhinney S, Pape WJ, Forster JE, et al. Human prion disease and relative risk associated with chronic wasting disease. Emerg Infect Dis. 2006 Oct;12(10):1527-35. Abstract
62. Lewis AM, Yu M, DeArmond SJ, et al. Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging. Arch Neurol. 2006 Feb;63(2):288-90.Full text Abstract
63. National Institute for Health and Care Excellence. Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. Jan 2020 [internet publication]Full text
64. National Institute for Health and Care Excellence. Donor breast milk banks: the operation of donor milk bank services. February 2010. [internet publication].Full text
65. Young GS, Geschwind MD, Fischbein NJ, et al. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1551-62.Full text Abstract
66. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009 Oct;132(Pt 10):2659-68.Full text Abstract
67. Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011 May 17;76(20):1711-9. Abstract
68. Groveman BR, Orrú CD1, Hughson AG, et al. Extended and direct evaluation of RT-QuIC assays for Creutzfeldt-Jakob disease diagnosis. Ann Clin Transl Neurol. 2016 Dec 27;4(2):139-144.Full text Abstract
69. Hermann P, Appleby B, Brandel JP, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021 Mar;20(3):235-246.Full text Abstract
70. Centers for Disease Control and Prevention. CDC’s Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD). 2018 [internet publication].Full text
71. Geschwind MD, Jay C. Assessment of rapidly progressive dementias. Concise review related to chapter 362: Alzheimer disease and other primary dementias. In: Braunwald E, Harrison TR, Fauci AS, et al, eds. Harrison's principles of internal medicine. New York, NY: McGraw-Hill; 2001:2391-2398.
72. Rabinovici GD, Wang PN, Levin J, et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology. 2006 Jan 24;66(2):286-7. Abstract
73. Prusiner SB, Bosque PJ. Prion diseases. In: Braunwald E, Harrison TR, Fauci AS, et al, eds. Harrison's principles of internal medicine. New York, NY: McGraw-Hill; 2001:2486-2491.
74. Collins S, McLean CA, Masters CL. Gerstmann-Sträussler-Scheinker syndrome,fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies. J Clin Neurosci. 2001 Sep;8(5):387-97. Abstract
75. Gambetti P, Kong Q, Zou W, et al. Sporadic and familial CJD: classification and characterisation. Br Med Bull. 2003;66:213-39. Abstract
76. American College of Radiology. ACR appropriateness criteria: movement disorders and neurodegenerative diseases. 2019 [internet publication].Full text
77. Shiga Y, Miyazawa K, Sato S, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology. 2004 Aug 10;63(3):443-9. Abstract
78. Finkenstaedt M, Szudra A, Zerr I, et al. MR imaging of Creutzfeldt-Jakob disease. Radiology. 1996 Jun;199(3):793-8. Abstract
79. Collie DA, Sellar RJ, Zeidler M, et al. MRI of Creuztfeldt-Jakob disease: imaging features and recommended MRI protocol. Clin Radiol. 2001 Sep;56(9):726-39. Abstract
80. Keohane C. Pulvinar sign on MRI images in variant Creutzfeldt-Jakob disease. Lancet. 2000 Apr 22;355(9213):1384. Abstract
81. Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt- Jakob disease. Lancet. 2000 Apr 22;355(9213):1412-8. Abstract
82. Steinhoff BJ, Zerr I, Glatting M, et al. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol. 2004 Nov;56(5):702-8. Abstract
83. Chitravas N, Jung RS, Kofskey DM, et al. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol. 2011 Sep;70(3):437-44.Full text Abstract
84. Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012 Oct 2;79(14):1499-506.Full text Abstract
85. Tschampa HJ, Neumann M, Zerr I, et al. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2001 Jul;71(1):33-9.Full text Abstract
86. Geschwind M, Haman A, Torres-Chae C, et al. CSF findings in a large United States sporadic CJD cohort. Neurology. 2007;68(suppl 1):A142.
87. Huntington's Disease Society of America. Genetic testing for Huntington’s disease: its relevance and implications. 2003. [internet publication].Full text
88. de Priester JA, Jansen GH, de Kruijk JR, et al. New MRI findings in Creutzfeldt-Jakob disease: high signal in the globus pallidus on T1-weighted images. Neuroradiology. 1999 Apr;41(4):265-8. Abstract
89. Satoh J, Kurohara K, Yukitake M, et al. The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol. 1999;41(4):216-25. Abstract
90. Satoh K, Shirabe S, Eguchi H, et al. 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol. 2006 Feb;26(1):45-52. Abstract
91. Chapman T, McKeel DW Jr, Morris JC. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology. 2000 Nov 14;55(9):1396-7. Abstract
92. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2006 Aug 22;67(4):637-43. Abstract
93. Moussavian M, Potolicchio S, Jones R. The 14-3-3 brain protein and transmissible spongiform encephalopathy. N Engl J Med. 1997 Mar 20;336(12):873-4 Abstract
94. Hsich G, Kenney K, Gibbs CJ, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996 Sep 26;335(13):924-30.Full text Abstract
95. Tschampa HJ, Kallenberg K, Urbach H, et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain. 2005 Sep;128(Pt 9):2026-33.Full text Abstract
96. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939-44. Abstract
97. Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007 Apr 10;68(15):1205-12. Abstract
98. Haik S, Brandel JP, Sazdovitch V, et al. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology. 2000 Nov 14;55(9):1401-4. Abstract
99. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(suppl):417-423. Abstract
100. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005 Dec 27;65(12):1863-72. Abstract
101. Catani M, Piccirilli M, Geloso MC, et al. Rapidly progressive aphasic dementia with motor neuron disease: a distinctive clinical entity. Dement Geriatr Cogn Disord. 2004;17(1-2):21-8. Abstract
102. Mackenzie IR, Feldman H. Neurofilament inclusion body disease with early onset frontotemporal dementia and primary lateral sclerosis. Clin Neuropathol. 2004 Jul-Aug;23(4):183-93. Abstract
103. Roberson ED, Hesse JH, Rose KD, et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology. 2005 Sep 13;65(5):719-25. Abstract
104. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998 Dec;51(6):1546-54. Abstract
105. Avanzino L, Marinelli L, Buccolieri A, et al. Creutzfeldt-Jakob disease presenting as corticobasal degeneration: a neurophysiological study. Neurol Sci. 2006 Jun;27(2):118-21. Abstract
106. Ferro JM. Vasculitis of the central nervous system. J Neurol. 1998 Dec;245(12):766-76. Abstract
107. Moore PM, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):10-22.Full text Abstract
108. Younger DS, Kass RM. Vasculitis and the nervous system. Historical perspective and overview. Neurol Clin. 1997 Nov;15(4):737-58. Abstract
109. Josephson SA, Papanastassiou AM, Berger MS, et al. The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg. 2007 Jan;106(1):72-5.Full text Abstract
110. Vernino S, Geschwind MD, Boeve B. Autoimmune encephalopathies. Neurologist. 2007 May;13(3):140-7. Abstract
111. Dropcho EJ. Paraneoplastic diseases of the nervous system. Curr Treat Options Neurol. 1999 Nov;1(5):417-427. Abstract
112. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul;123 ( Pt 7):1481-94.Full text Abstract
113. Tuzun E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist. 2007 Sep;13(5):261-71. Abstract
114. Rosenbloom MH, Smith S, Akdal G, et al. Immunologically mediated dementias. Curr Neurol Neurosci Rep. 2009 Sep;9(5):359-67.Full text Abstract
115. Kothbauer-Margreiter I, Sturzenegger M, Komor J, et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol. 1996 Aug;243(8):585-93. Abstract
116. Seipelt M, Zerr I, Nau R, et al. Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt- Jakob disease. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):172-6.Full text Abstract
117. Josephs KA, Rubino FA, Dickson DW. Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology. 2004 Jun;24(2):149-52. Abstract
118. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006 Feb;63(2):197-202.Full text Abstract
119. Chong JY, Rowland LP. What's in a NAIM? Hashimoto encephalopathy, steroid-responsive encephalopathy associated with autoimmune thyroiditis, or nonvasculitic autoimmune meningoencephalitis? Arch Neurol. 2006 Feb;63(2):175-6. Abstract
120. Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003 Feb;60(2):164-71.Full text Abstract
121. Geschwind MD, Yoon G, Goldman J. Adult-onset genetic disorders involving the frontal lobes. In: Miller BL, Cummings JF, eds. The human frontal lobes: functions and disorders. 2nd ed. New York: Guilford Press; 2007:552-575.
122. Geschwind MD, Haman A, Miller BL. Rapidly progressive dementia. Neurol Clin. 2007 Aug;25(3):783-807, vii. Abstract
123. Cavalier L, Ouahchi K, Kayden HJ, et al. Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. Am J Hum Genet. 1998 Feb;62(2):301-10.Full text Abstract
124. Kitzberger R, Madl C, Ferenci P. Wilson disease. Metab Brain Dis. 2005 Dec;20(4):295-302. Abstract
125. Ross ME, Jacobson IM, Dienstag JL, et al. Late-onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer rings. Ann Neurol. 1985 Apr;17(4):411-3. Abstract
126. Molina JA, Jimenez-Jimenez FJ, Calandre L. Bismuth encephalopathy. Neurology. 1994 Mar;44(3 Pt 1):582. Abstract
127. Teepker M, Hamer HM, Knake S, et al. Myoclonic encephalopathy caused by chronic bismuth abuse. Epileptic Disord. 2002 Dec;4(4):229-33. Abstract
128. Jungreis AC, Schaumburg HH. Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol). Neurology. 1993 Jun;43(6):1265. Abstract
129. Le Quesne PM. Metal-induced diseases of the nervous system. Br J Hosp Med. 1982 Nov;28(5):534-8. Abstract
130. Timmermans M, Carr J. Neurosyphilis in the modern era. J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1727-30.Full text Abstract
131. Fallon BA, Nields JA, Parsons B, et al. Psychiatric manifestations of Lyme borreliosis. J Clin Psychiatry. 1993 Jul;54(7):263-8. Abstract
132. Kaplan RF, Jones-Woodward L. Lyme encephalopathy: a neuropsychological perspective. Semin Neurol. 1997 Mar;17(1):31-7. Abstract
133. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008 Mar 25;70(13):992-1003. Abstract
134. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990 Nov 22;323(21):1438-44. Abstract
135. Louis ED, Lynch T, Kaufmann P, et al. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol. 1996 Oct;40(4):561-8. Abstract
136. Ghezzi A, Zaffaroni M. Neurological manifestations of gastrointestinal disorders, with particular reference to the differential diagnosis of multiple sclerosis. Neurol Sci. 2001 Nov;22 Suppl 2:S117-22. Abstract
137. Durand DV, Lecomte C, Cathebras P, et al. Whipple disease: clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Societe Nationale Francaise de Medecine Interne. Medicine (Baltimore). 1997 May;76(3):170-84. Abstract
138. Zoonotic Disease Division of Emerging and other Communicable Diseases Surveillance and Control. Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation. Geneva, Switzerland: WHO; 1998.Full text
139. Shaked GM, Engelstein R, Avraham I, et al. Valproic acid treatment results in increased accumulation of prion proteins. Ann Neurol. 2002 Oct;52(4):416-20. Abstract
140. Sander JW, Duncan JS. Valproic acid and prion proteins. Ann Neurol. 2003 May;53(5):688-9. Abstract
141. US Food and Drug Administration. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2018 [internet publication].Full text
Use of this content is subject to our disclaimer